Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil for Fuchs Endothelial Corneal Dystrophy After Cataract Surgery and Descemetorhexis
2022-502643-35-00Phase 3Completed
- Sponsor
- Kowa Research Institute
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Fuchs endothelial dystrophy (FED) comparing Ripasudil eye drops with Placebo eye drops (2 arms). Primary endpoint: Time to ≥40 ETDRS letter improvement in BCVA. Started Aug 2023; status: completed.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on 2022-502643-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502643-35-00.